HomeFinTechMemphasys: Completes maiden sale of Felix

Memphasys: Completes maiden sale of Felix

Date:

UK Tribunal Rules Visa and Mastercard Interchange Fees Breach Competition Law

Landmark decision finds payment giants’ multilateral interchange fees unlawful,...

UK Tribunal Rules Visa and Mastercard Fees Violate Competition Law

Landmark Decision Could Reshape Payment Processing Landscape Highlights: The UK...

Belgium Prosecutors Investigate Worldline Local Unit for Potential Misconduct

An In-Depth Look into the Probe and Its Implications...

Memphasys Completes maiden sale of Felix

  • Reproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of Felix
  • The sale was made to Diagens Biotechnology, which is a Chinese company that manufacturers and distributes human reproduction products across China
  • This represents a major milestone for Memphasy as it increases its exposure to the Chinese market, which is the largest IVF market in the world
  • Felix is Memphasy novel device that quickly and gently separates high-quality sperm from a sample for use in IVF procedures
  • The company was up 14.3 per cent on the market with shares trading at 12 cents
Exit mobile version